ALL - Network of Cancer Research

YX-2-107, a PROTAC, is a Selective CDK6 Degrader

Louis Gilman January 12, 2023

Ph+ ALL (Philadelphia chromosome-positive acute lymphoblastic leukemia) is a rare subtype of leukemia characterized by the abnormal formation of the Philadelphia chromosome, which occurs when pieces of chromosomes 9 and…

Acute Lymphoblastic Leukemia Cancer Chronic Myeloid Leukemia

Vamotinib (PF-114) is a Potent, Selective and Orally Active Tyrosine Kinase Inhibitor

Louis Gilman August 13, 2022

BCR-ABL, a fusion gene, is a mutation that is formed by the combination of two genes, BCR and ABL. The BCR gene is normally on chromosome number 22. The ABL…

Breast Cancer

YX-2-107, a PROTAC, is a Selective CDK6 Degrader

Vamotinib (PF-114) is a Potent, Selective and Orally Active Tyrosine Kinase Inhibitor

You Missed

BI 7446 is a STING Agonist for Immuno-oncology Research

JNJ-38877605 is an Orally Active c-Met Inhibitor for Solid Tumour Research

OATD-02 is an Orally Active Arginase 1/2 Inhibitor for Melanoma Research

INCB086550 is an Orally Active PD-L1 Inhibitor for Multiple Cancers Research